This trial included 18 patients with advanced NSCLC with a PD‐L1 TPS >1% and randomized the patients to pembrolizumab with low‐dose SNK01 (2 × 109 cells/dose) or high‐dose SNK01 (4 × 109 cells/dose), or pembrolizumab monotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.